blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3954708

EP3954708 - TRANSGENE GENETIC TAGS AND METHODS OF USE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  12.08.2022
Database last updated on 07.06.2024
FormerThe application has been published
Status updated on  14.01.2022
Most recent event   Tooltip26.02.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Seattle Children's Hospital (DBA Seattle Children's Research Institute)
1900 Ninth Avenue
Seattle, WA 98101 / US
[2022/07]
Inventor(s)01 / JENSEN, Michael C.
Seattle, WA 98101 / US
02 / JOHNSON, Adam
Seattle, WA 98101 / US
 [2022/07]
Representative(s)Plougmann Vingtoft a/s
Strandvejen 70
2900 Hellerup / DK
[2022/07]
Application number, filing date21180797.908.04.2015
[2022/07]
Priority number, dateUS201461977751P10.04.2014         Original published format: US 201461977751 P
US201461986479P30.04.2014         Original published format: US 201461986479 P
US201462058973P02.10.2014         Original published format: US 201462058973 P
US201462088363P05.12.2014         Original published format: US 201462088363 P
US201462089730P09.12.2014         Original published format: US 201462089730 P
US201462090845P11.12.2014         Original published format: US 201462090845 P
[2022/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3954708
Date:16.02.2022
Language:EN
[2022/07]
Search report(s)(Supplementary) European search report - dispatched on:EP25.11.2021
ClassificationIPC:C07K16/28, A61K39/39
[2022/07]
CPC:
C12N5/0636 (EP,AU,IL,KR,RU,US); C12N5/0638 (EP,AU,IL,KR,RU); C12N15/86 (IL,KR);
C07K16/2803 (AU,IL,US); A61K35/17 (IL,US); A61K35/28 (IL,US);
A61K38/1774 (EP,IL,US); A61K38/179 (EP,IL,US); A61K38/1793 (EP,IL,US);
A61K39/3955 (IL,US); A61K39/4611 (EP,AU,KR,RU); A61K39/4631 (EP,AU,KR,RU);
A61K39/464412 (EP,AU,KR,RU); A61P1/04 (EP,IL); A61P1/18 (EP,IL);
A61P13/12 (EP,IL); A61P15/00 (EP,IL); A61P25/00 (EP,IL);
A61P31/12 (EP,IL); A61P35/00 (EP,AU,IL,RU); A61P35/02 (EP,AU,IL);
A61P37/06 (EP,IL); A61P43/00 (EP,IL); C07K14/705 (IL,RU);
C07K14/7051 (AU,IL,KR,US); C07K14/70517 (IL,US); C07K14/70521 (IL,US);
C07K14/70578 (IL,US); C07K14/71 (IL,US); C07K14/7151 (IL,US);
C07K16/2818 (IL,US); C07K16/32 (IL,US); C12N15/62 (IL,RU);
C12N15/85 (IL,US); C12N9/12 (EP,AU,IL,US); C12Y207/10001 (EP,AU,IL,US);
A61K2035/124 (IL,US); A61K2039/505 (AU,IL,US); A61K2039/5156 (IL,US);
A61K2039/5158 (IL,US); A61K2039/572 (AU,IL,US); C07K2317/14 (EP,AU,IL,KR,US);
C07K2317/524 (IL,US); C07K2317/526 (IL,US); C07K2317/53 (IL,US);
C07K2317/622 (EP,AU,IL,KR,US); C07K2317/73 (AU,IL,US); C07K2319/00 (IL,KR);
C07K2319/02 (AU,IL,US); C07K2319/03 (AU,IL,US); C07K2319/33 (AU,IL,US);
C12N2510/00 (IL,US); C12N2740/15041 (IL,KR); C12N2800/90 (IL,US);
C12N2820/002 (IL,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/37]
Former [2022/07]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:TRANSGENE GENETISCHE ETIKETTEN UND VERFAHREN ZUR VERWENDUNG[2022/07]
English:TRANSGENE GENETIC TAGS AND METHODS OF USE[2022/07]
French:MARQUEURS GÉNÉTIQUES DE TRANSGÈNE ET PROCÉDÉS D'UTILISATION[2022/07]
Examination procedure08.08.2022Amendment by applicant (claims and/or description)
08.08.2022Examination requested  [2022/37]
08.08.2022Date on which the examining division has become responsible
Parent application(s)   TooltipEP15776745.0  / EP3129405
EP21157809.1
Fees paidRenewal fee
10.09.2021Renewal fee patent year 03
10.09.2021Renewal fee patent year 04
10.09.2021Renewal fee patent year 05
10.09.2021Renewal fee patent year 06
10.09.2021Renewal fee patent year 07
02.03.2022Renewal fee patent year 08
27.02.2023Renewal fee patent year 09
26.02.2024Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO9818923  (SEARLE & CO [US], et al) [A] 1-15* the whole document *;
 [A]WO0023573  (HOPE CITY [US]) [A] 1-15 * claim 10 *;
 [A]WO03025228  (PROTEOLOGICS INC [US], et al) [A] 1-15 * the whole document *;
 WO2005017102  [ ] (DIADEXUS INC [US], et al) [ ] * sequence 110 *;
 [A]WO2010141543  (TARGETED MOLECULAR DIAGNOSTICS LLC [US], et al) [A] 1-15 * sequence 2 *;
 [A]WO2011056894  (JENSEN MICHAEL C [US]) [A] 1-15 * paragraphs [0045] - [0046] *;
 [A]WO2014031687  (JENSEN MICHAEL [US], et al) [A] 1-15 * sequence 11 *;
 [A]  - "SubName: Full=Receptor tyrosine-protein kinase erbB-2 {ECO:0000313|Ensembl:ENSP00000464252}; Flags: Fragment;", UniProt, (20121003), Database accession no. J3QRJ7, URL: EBI, XP002771300 [A] 1-15 * sequence . *
 [A]  - "Human splice variant protein expressed in ovary cells DEX0487_002.orf.4.", Geneseq, (20050505), Database accession no. ADY30515, URL: EBI, XP002771301 [A] 1-15 * sequence . *
 [A]  - X. WANG ET AL, "A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells", BLOOD, (20110804), vol. 118, no. 5, doi:10.1182/blood-2011-02-337360, ISSN 0006-4971, pages 1255 - 1263, XP055062819 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1182/blood-2011-02-337360
 [A]  - M. HUDECEK ET AL, "Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells", CLINICAL CANCER RESEARCH, (20130425), vol. 19, no. 12, doi:10.1158/1078-0432.CCR-13-0330, ISSN 1078-0432, pages 3153 - 3164, XP055177780 [A] 1-15 * page 3154, column r, paragraph 5 *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0330
 [A]  - J. T. GARRETT ET AL, "Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu", THE JOURNAL OF IMMUNOLOGY, US, (20070601), vol. 178, no. 11, doi:10.4049/jimmunol.178.11.7120, ISSN 0022-1767, pages 7120 - 7131, XP055230038 [A] 1-15 * abstract *

DOI:   http://dx.doi.org/10.4049/jimmunol.178.11.7120
by applicant   - GARRETT et al., J. Immunology, (20070000), vol. 178, page 7120
    - CHO et al., Nature, (20030000), vol. 421, page 756
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.